Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2021

Critical Period After Stroke Study (CPASS): A phase II clinical trial
testing an optimal time for motor recovery after stroke in humans
Alexander W. Dromerick
Shashwati Geed
Jessica Barth
Kathaleen Brady
Margot L. Gianetti

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Alexander W. Dromerick, Shashwati Geed, Jessica Barth, Kathaleen Brady, Margot L. Gianetti, Abigail
Mitchell, Matthew A. Edwardson, Ming T. Tan, Yizhao Zhou, Elissa L. Newport, and Dorothy F. Edwards

Critical Period After Stroke Study (CPASS): A phase II
clinical trial testing an optimal time for motor recovery
after stroke in humans
Alexander W. Dromericka,b,1,2, Shashwati Geeda,b,1, Jessica Bartha,c, Kathaleen Bradya, Margot L. Giannettia,
Abigail Mitchella, Matthew A. Edwardsonb, Ming T. Tanb,d, Yizhao Zhoud, Elissa L. Newportb,3,
and Dorothy F. Edwardse,f
a
Research Division, MedStar National Rehabilitation Hospital, Washington, DC 20010; bCenter for Brain Plasticity and Recovery, Departments of
Rehabilitation Medicine and Neurology, Georgetown University Medical Center, Washington, DC 20057; cProgram in Physical Therapy, Washington
University in St. Louis, St. Louis, MO 63110; dDepartment of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center,
Washington, DC 20057; eDepartment of Kinesiology, University of Wisconsin–Madison, Madison, WI 53706; and fDepartment of Medicine, University of
Wisconsin–Madison, Madison, WI 53706

Restoration of human brain function after injury is a signal
challenge for translational neuroscience. Rodent stroke recovery
studies identify an optimal or sensitive period for intensive motor
training after stroke: near-full recovery is attained if task-specific
motor training occurs during this sensitive window. We extended
these findings to adult humans with stroke in a randomized controlled trial applying the essential elements of rodent motor training
paradigms to humans. Stroke patients were adaptively randomized
to begin 20 extra hours of self-selected, task-specific motor therapy
at ≤30 d (acute), 2 to 3 mo (subacute), or ≥6 mo (chronic) after
stroke, compared with controls receiving standard motor rehabilitation. Upper extremity (UE) impairment assessed by the Action Research Arm Test (ARAT) was measured at up to five time points. The
primary outcome measure was ARAT recovery over 1 y after stroke.
By 1 y we found significantly increased UE motor function in the
subacute group compared with controls (ARAT difference = +6.87 ±
2.63, P = 0.009). The acute group compared with controls showed
smaller but significant improvement (ARAT difference = +5.25 ±
2.59 points, P = 0.043). The chronic group showed no significant
improvement compared with controls (ARAT = +2.41 ± 2.25, P =
0.29). Thus task-specific motor intervention was most effective
within the first 2 to 3 mo after stroke. The similarity to rodent model
treatment outcomes suggests that other rodent findings may be
translatable to human brain recovery. These results provide empirical evidence of a sensitive period for motor recovery in humans.
stroke rehabilitation
factors

recover the necessary upper extremity (UE) function for usual
activities by 6 mo, when motor recovery typically plateaus
(12–14). To date the majority of randomized stroke rehabilitation trials have demonstrated limited efficacy in motor recovery
(15–26).
Importantly, findings from rodent models of stroke suggest
that there may exist brief, time-sensitive phenomena when the
poststroke circuitry is especially responsive to training. Forelimb
motor training during these preferred time windows is associated
with nearly full recovery of forelimb function compared with
animals given the same motor training outside the window (1, 5,
10). Biernaskie et al. (1) randomized lesioned rodents to receive
focused forelimb motor training at 5, 14, or 30 d after injury.
They found the best response to training started at 5 d postlesion, an intermediate response occurred at 14 d, and training
started at 30 d showed no difference compared with controls.
Significance
Restoration of postinjury brain function is a signal neuroscience challenge. Animal models of stroke recovery demonstrate
time-limited windows of heightened motor recovery, similar to
developmental neuroplasticity. However, no equivalent windows have been demonstrated in humans. We report a randomized controlled trial applying essential elements of animal
motor training paradigms to humans, to determine the existence of an analogous sensitive period in adults. We found a
similar sensitive or optimal period 60 to 90 d after stroke, with
lesser effects ≤30 d and no effect 6 mo or later after stroke.
These findings prospectively demonstrated the existence of a
sensitive period in adult humans. We urge the provision of
more intensive motor rehabilitation within 60 to 90 d after
stroke onset.
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estoration of human brain function after anatomic injury is a
challenge to current neuroscience. Importantly, findings in
animal models suggest that there are short-lived phenomena after
stroke in mature animals that are similar to early developmental
periods of heightened neural plasticity (1–6). Within days after a
neuronal injury, rats show time-sensitive increases in dendritic
branching peaking 2 to 3 wk postinjury (7), followed by a behaviordependent pruning of newly formed dendritic arbors (8, 9). Intensive motor training provided to rodents within such periods has
been shown to restore full motor function (1, 5, 10). However,
there has previously been no direct evidence of similar timelimited responsiveness to intensive motor training in human
adults. Here we present such evidence: a randomized controlled
trial supporting the existence of such a sensitive period for motor
recovery after stroke in human patients.
Restoration of human brain function after a neuroanatomical
injury like stroke is a pressing challenge not only for scientific
reasons but also for its profound clinical significance. Americans
suffer a stroke once every 40 s, with ∼750,000 new strokes
each year (11). Two-thirds of the individuals with stroke do not
PNAS 2021 Vol. 118 No. 39 e2026676118
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Purposeful forelimb activity is an important component of this
time-sensitive recovery: Animals housed in enriched environments that encouraged exploratory forelimb movements demonstrated superior functional recovery compared with animals
housed in standard cages after stroke (5). Zeiler et al. (10) recently demonstrated that mice given a second ischemic lesion to
the medial premotor cortex show nearly full recovery after previously incomplete forelimb motor recovery from a primary ischemic lesion to the caudal forelimb area. The second lesion was
hypothesized to reopen a neuroplastic window closed after the
first lesion. Analogous phenomena have not yet been demonstrated in human adults after stroke. In this paper we will present
findings that demonstrate the existence of a poststroke sensitive
period in adult humans.
These time-sensitive improvements in motor function after
stroke have also been linked to a period of heightened physiological neuroplasticity, similar to the critical or sensitive periods
observed in juvenile circuitry at various times in the developing
nervous system (27–30). A critical or sensitive period, which
typically manifests in the early developing nervous system, is a
time-limited window of heightened neuroplasticity when neural
circuits are highly malleable and especially responsive to external
stimuli, which can shape the resulting connectivity patterns of the
circuitry (28, 31–33). After stroke to the motor system in rodents
a similar sensitive period is thought to be triggered in perilesional tissue by the cascade of events that occur from the neural
injury, beginning with the responses of surrounding cells and
then the loss of input to the connected neurons beyond the infarct (29, 30, 34–37). Changes in the perilesional region are hypothesized to create the cellular and molecular context (37–40)
in which new or enhanced neural connections and therefore new
pathways for motor control can be produced. However, this occurs only if training and practice, reinforcing the appropriate
signals for effective motor behavior, takes place simultaneously.
Importantly, training before or after a receptive neural context is
in place may have no functional effect (1). Indeed, intensive
training too soon may result in lesion expansion (41, 42) and reduce benefits of subsequent recovery in rodents (43). Similar
negative effects of training too early have been reproduced in
human stroke trials (16, 17). In the absence of training, no connections or dysfunctional connections may develop (8, 44, 45).
It may be surprising to suggest sensitive periods that are
manifest in adult circuitry, since most well-known critical periods
occur during early development (33, 46–50). However, there are
examples of the adult neural circuits showing opening or reopening
of critical periods as a result of environmental and epigenetic triggers. For example, bonding in sheep occurs in mother ewes within 2
to 4 h (up to 24 h) of giving birth; during this brief period (but not
before or after) the ewe will permit a lamb to nuzzle and she will
become imprinted on its smell (51, 52). Chronic administration of
fluoxetine in adult rats reopens the ocular dominance plasticity and
leads to recovery of adult amblyopia (53). Valproate has been
demonstrated to reopen critical period-like learning in human
adults for absolute pitch discrimination (54), which ordinarily occurs
only during early development (55, 56). Several recent studies have
demonstrated that histone acetylation in the adult brain, through
epigenetic remodeling of the chromatin structure, reopens critical
period-like plasticity in the adult visual cortex (57–59). Of note,
exposure of adult animals to enriched environments (60) reopens
critical period plasticity in adult rats through epigenetic modifications triggered by the histone acetylation mechanism.
The Present Study
The Critical Periods After Stroke Study (CPASS) is a phase II,
randomized, controlled trial designed to test if a critical or
sensitive period exists after stroke during which patients are
particularly responsive to intensive motor training. If a critical or
sensitive period is present, then intensive motor therapy during
2 of 10 | PNAS
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this period should lead to superior and sustained UE motor
outcomes, as compared with the same amount of intensive motor
therapy provided at other times. In the United States, nearly all
patients receive standard rehabilitation therapies; these constitute a barrier to experimental manipulation because of resistance
from institutional review boards and attitudes and beliefs of
clinicians and patients. Our experimental study-related treatment, provided to participants beyond their standard rehabilitation therapy, was devised to standardize treatment procedure
and intensity across groups regardless of treatment location
(hospital or home). This bolus of additional motor training will
hereafter be referred to as intensive motor therapy. As described
in detail in Materials and Methods, it consisted of 20 h of UE
motor training based on a standardized yet individualized
shaping protocol. We hypothesized that, compared with individuals randomized to the control condition or to the subacute (2
to 3 mo after onset) or chronic (6 to 9 mo after onset) time
points, persons randomized to the early (acute) time point would
show greater UE motor improvement as measured by the Action
Research Arm Test (ARAT) (61) assessed during 1 y poststroke.
However, calculating this outcome effect in humans is somewhat
more complex than assessing an effect at a single time point in
rodents. While time of intensive training and measuring outcomes can be precise when administered in the laboratory, in
humans the assessment at time of stroke, provision of training,
and assessment at 6 and 12 mo may occur only approximately at
the desired time points, due to the availability of the patients and
their other life circumstances. In addition, with the smaller effects
expected in humans (who receive training in addition to standard
care) as compared with rodents (from whom we can withhold
treatment in the controls), we need to carefully consider the differences between groups in how much improvement remains
possible in the types of movements assessed by the ARAT before
hitting the ARAT ceiling. Our analysis is therefore not of the raw
ARAT score at the 1-y time point after stroke—which would be
confounded by all of these other variables—but instead is of each
individual patient’s raw ARAT score improvement over the year,
taking into account the starting ARAT score at randomization, the
precise days at which the starting assessment, treatment, 6-mo,
and 12-mo assessments occurred, and the proportion of remaining
improvement that was possible on the ARAT scale. These variables are taken into account through a longitudinal unbalanced
repeated measures analysis that is explained in more detail in
Materials and Methods and in SI Appendix.
The overall goal for the CPASS trial was primarily to elicit a
timing signal for critical period plasticity in adult humans recovering from stroke. If a critical period was identified, then
future studies can optimize the content and dose of intensive
motor therapy needed for maximum recovery, thus best improving clinical outcomes in persons with stroke.
Results
Study Participants and Baseline Characteristics. Table 1 presents the
study inclusion and exclusion criteria. We screened 2,077 patients admitted for stroke rehabilitation at MedStar National
Rehabilitation Hospital between November 2014 and October
2018 in order to enroll 72 participants. Participants were adaptively randomized to the acute (n = 16), subacute (n = 17), chronic
(n = 20), or control (n = 19) groups. Fig. 1 presents the CONSORT diagram. Fig. 2 illustrates the flow of patients through the
study. Seventy of the 72 enrolled participants completed the primary outcome assessment at 12 mo. Table 2 shows the key participant demographics and study group baseline characteristics.
There were no significant differences among the treatment
groups for any of the demographic variables. Consistent with
the general population of patients admitted to MedStar National
Rehabilitation Hospital and the population of Washington,
DC, the CPASS sample was predominantly African American
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Inclusion criteria
1. Ischemic or hemorrhagic stroke (with confirmatory neuroimaging)
within 28 d of admission to inpatient rehabilitation
2. Age ≥21 y
3. Able to participate in first study-related treatment session within
30 d of stroke onset
4. Able to participate in all study-related activities, including 1-y
follow up and blood draws
5. Persistent hemiparesis leading to impaired UE function as indicated
by a score ≥1 on the NIHSS motor arm score, and motor impairment
judged clinically appropriate as defined by one or more of the
following:
a. Proximal UE voluntary activity indicated by a score of ≥3 on the
upper arm item of the motor assessment scale; wrist and finger
movements are not required
b. Manual muscle test (MMT) score ≥2 on shoulder flexion and
either elbow flexion or extension or
c. Active range of motion (AROM) to at least 50% of range in
gravity eliminated position for shoulder flexion or abduction,
and for any of the following motions: elbow flexion, elbow
extension, wrist flexion, wrist extension, finger flexion or finger
extension
6. Score of ≤8 on the Short Blessed Memory Orientation and
Concentration scale
7. Follows two-step commands
8. No UE injury or conditions that limited use prior to the stroke
9. Prestroke independence: Modified Rankin Scale score of 0 or 1
Exclusion criteria
1. Inability to give informed consent
2. Prior stroke with persistent motor impairment or other disabling
neurologic conditions such as multiple sclerosis, Parkinsonism, ALS,
dementia requiring medication
3. Rapidly evolving motor function
4. Clinically significant fluctuations in mental status in the 72 h prior
to randomization
5. Hemispatial neglect as determined by an asymmetry >3 errors on
the Mesulam symbol cancellation test
6. Not independent prior to stroke (determined by scores of <95 on
Barthel Index or >1 on modified Rankin scale
7. Dense sensory loss indicated by a score of 2 on NIHSS sensory item
8. Ataxia out of proportion to weakness in the affected arm as
defined by a score ≥1 on the NIHSS limb ataxia item
9. Active or prior (within 2 y) psychosis
10. Active or prior (within 2 y) substance abuse
11. Not expected to survive 1 y due to other illnesses (cardiac disease,
malignancy, etc.)
12. Received UE botulinum toxin within 6 mo (other medications do
not exclude)
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Adapted from ref. 100, which is licensed under CC BY 4.0.

(83.3%) and 50% female. The mean age of the participants was
62.8 ± 11.5 y. Most of the participants had ischemic strokes with a
mean National Institutes of Health Stroke Scale (NIHSS) score of
4.9 ± 1.7. The mean time from stroke onset to randomization was
15.4 ± 4.5 d. The dominant side of the body was affected in 45.8% of
the participants. Individual motor recovery trajectories throughout
the 12-mo study duration, measured using ARAT on the affected
UE, are shown in Fig. 3. SI Appendix, Table S1 shows the study
measures applied at different time points throughout the study.
Significant Effect of Timing the Therapy Manipulation Early after Stroke:
Subacute and Acute Groups Improve Significantly More than Controls.

A longitudinal (unbalanced repeated measures) model computed
by the GEE (generalized estimating equations) was utilized for data

analysis to test differences in overall UE recovery of the four groups
between baseline and the 12-mo time point. An unbalanced repeated measures model is necessary to accommodate missing data
and the actual times of measurement around the original preset
assessment schedule (62). Unbalanced designs have become the
rule rather than the exception in human clinical trials, as patient
follow-ups rarely occur at exactly planned, equally spaced time
points (63–65). This analytic approach was selected because it uses
all available data for each subject and allows specification of both
time-varying and individual difference variables within the same
analysis (66, 67). The longitudinal model, which focuses on average changes in response over time and the impact of covariates on
these changes, was used to determine whether additional motor
training introduced at different time points after stroke affected
UE motor recovery. Longitudinal ARAT scores from the four
groups were used to estimate the overall UE motor recovery between baseline and the 12-mo time point. These scores were adjusted for baseline ARAT scores and days since stroke onset to the
baseline evaluation.
Fig. 3 shows the individual participants’ trajectories in raw
total ARAT scores poststroke, organized by treatment group.
ARAT scores in the chronic and the control groups at 6 mo and
12 mo are spread throughout the ARAT score range, suggesting
relatively poor recovery for many individuals. In contrast, subacute group scores at 6 mo tend to cluster in the top half of the
ARAT score range and do so even more at 12 mo.
Fig. 4 presents the mean total ARAT scores and SEs for each
group over time from the longitudinal model, computed using
the GEE method, as is required for appropriate analysis due to
the unequal spacing of assessments and training (these data
along with ARAT scores from pre- and posttreatment are shown
in SI Appendix, Fig. S1). These group means bear out what can
be seen in the individual trajectories in Fig. 3. The subacute group
(given 20 extra therapy hours initiated 2 to 3 mo poststroke) improved significantly more than the control group (difference between subacute and control ARAT = +6.87 ± 2.63 points, P =
0.009). Similarly, the acute group (20 extra therapy hours initiated
within the 30-d poststroke window) showed significantly more
improvement than the controls (difference in ARAT between
acute and control groups = +5.25 ± 2.59 points, P = 0.043). In
contrast, the chronic group (20 extra therapy hours initiated at ≥6
mo poststroke) showed no significant difference compared with
controls (difference in ARAT = +2.41 ± 2.25, P = 0.29). Baseline
ARAT (P < 0.001) and number of days from stroke onset to
randomization (P = 0.003) were other significant predictors of the
mean ARAT score.
Notably, the improvement in the subacute group was greater
than the minimal clinically important difference (MCID) for
mean ARAT scores compared with the control group (ARAT
MCID = 5.7 points) (68, 69). Thus, the increase in arm function
recovery was not only statistically significant but the magnitude
of improvement was large enough to be perceived as functionally
meaningful by the subacute group participants. The acute group
improvement was statistically significant but did not achieve the
magnitude needed to meet MCID criteria. The magnitude of
additional recovery in the chronic group was not statistically
significant and did not exceed the ARAT MCID.
Discussion
CPASS is the first early stroke rehabilitation trial in humans to
demonstrate superior recovery of UE motor function in an experimental group (at 2 to 3 mo after and at 30 d) compared with
a control group receiving traditional occupational and physical
therapy at 12 mo. The same effect was not observed when additional therapy was initiated 6 mo poststroke. The methodology
of this study was carefully designed to determine whether human
responsiveness is analogous to rodent responses when the study
elements were matched as closely as possible without substantially
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Table 1. CPASS inclusion and exclusion criteria

Fig. 1. CONSORT diagram for the CPASS trial. Seventy-two individuals were adaptively randomized to receive CPASS therapy acute (≤30 d poststroke),
subacute (2 to 3 mo), chronic (≥6 mo poststroke), or the control group.
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disrupting the standard of care. Our study goal was met: Under
rigorously controlled conditions for a human trial in a realistic
clinical setting we are able to present strong evidence for what
appears to be, indeed, a critical or sensitive period in human
stroke recovery. We showed that study-specific UE motor rehabilitation and time poststroke combine synergistically during a
time-limited window to produce enhanced UE motor recovery
after stroke. Similar gains in recovery were absent when the same

motor rehabilitation was provided at a later time. Moreover, we
have shown that such intensive motor training is not only effective
but is also feasible within current US acute and subacute
rehabilitation treatment environments.
There are several important findings from this trial. First,
study-specific intervention in the subacute phase (2 to 3 mo
poststroke) led to significantly greater UE motor recovery compared with controls. Second, the acute group (≤30 d poststroke)

Fig. 2. Study design. Baseline assessment occurred <30 d from stroke onset, and participants were randomized to one of four groups: acute, received
additional 20 h of therapy initiated within 30 d from stroke onset; subacute, received additional 20 h initiated within 2 to 3 mo from stroke onset; chronic,
received additional 20 h 6 to 7 mo after onset; controls, received standard rehabilitation. Adapted from ref. 100, which is licensed under CC BY 4.0.
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Table 2. Demographic characteristics and scores on baseline study measures (n = 72) shown by group

Age, y
Sex (female)
Race
Caucasian
African American
American Indian, Alaskan
Asian
Native Hawaiian, Pacific Islander
Dominant UE affected
Stroke type
Ischemic
Hemorrhagic
Total NIHSS
Total ARAT
Days from stroke onset to randomization
Hours of study-specific therapy received

Total sample (n = 72)

Acute (n = 16)

Subacute (n = 17)

Chronic (n = 20)

Control (n = 19)

62.8 ± 11.5
36 (50)

61.8 ± 11.3
11 (68.8)

63.9 ± 10.8
6 (35.2)

67.3 ± 9.8
11 (55)

10 (13.9)
60 (83.3)
0
1 (1.4)
1 (1.4)
33 (45.8)

1 (6.3)
13 (81.3)
0
1 (6.3)
1 (6.3)
9 (56.2)

2 (11.8)
15 (88.2)
0
0
0
8 (47)

5 (25)
15 (75)
0
0
0
9 (45)

2 (10.5)
17 (89.5)
0
0
0
7 (36.8)

69 (95.8)
3 (4.2)
4.9 ± 1.7
15.8 ± 13.8
15.4 ± 4.5
19.7 ± 1.7

16 (100)
0
4.9 ± 1.9
16.8 ± 16.2
15.6 ± 4
18.8 ± 2.9

17 (100)
0
4.9 ± 2.1
13.4 ± 11.4
14.8 ± 4.6
20 ± 0.3

17 (85)
3 (15)
4.6 ± 1.5
20.3 ± 15.7
15.3 ± 4.4
20.2 ± 0.7

19 (100)
0
5.3 ± 1.6
12.3 ± 10.5
16.1 ± 5
—

58 ± 12.6
8 (42.1)
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showed smaller but statistically significant improvement over controls. Third, the same intervention provided later, at ≥6 mo to the
chronic group, showed no significant differences compared with
controls. Fourth, the early gains in motor recovery observed in the
subacute and acute groups were sustained long-term for at least up

to 12 mo after stroke. Finally, subacute group gains in UE motor
recovery were large enough in magnitude to meet the published
criteria for meaningful clinical improvement on the measure.
What is the clinical meaning of these improved motor skills?
Clinical trialists use the MCID as a means of determining the

Fig. 3. (A–D) Individual trajectories of raw ARAT scores posttroke, by treatment group. Vertical gray bars show average timing of the intervention in
each group.
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Baseline demographics of study participants per group. Numbers in parentheses indicate percentages. Categorical variables are shown as counts and
percentages; continuous variables are described using means and SDs. Controls received standard rehabilitation; therefore controls’ “hours of study-specific
therapy received” is empty.

Total ARAT mean by group
55

50

45

40

35

ARAT

Study Group
Acute

30

Subacute
Chronic

25

Control
20

15

10

5

0
Baseline

6m

12m

Time Point
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Fig. 4. Mean total ARAT scores (with SEs) for each group at each time point,
from the longitudinal model. (The 6-mo assessment score for the chronic
group is their pretreatment assessment.)

effectiveness of the intervention on domains of interest to the
person. The MCID has been defined as “the smallest difference
in score in the domain of interest which patients perceive as
beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient’s
management” (68). In this study, the MCID (68, 70–72) refers to
improved ability of the participants to execute functional
movements associated with performance of activities of daily
living requiring hand and arm use. The subacute group achieved
improvement in UE function that is greater than the ARAT
MCID. Although the acute group showed statistically significant
increase in ARAT compared with controls, the acute group’s
scores narrowly missed the MCID threshold. Although most of
our participants did not achieve a full resolution of their motor
impairment, our results are consistent with recent rodent motor
recovery findings, which also demonstrate residual forelimb
motor impairments. Rodent studies create precise reproducible
brain lesions; this differs from the clinical situation in human
trials, where the lesions are more heterogeneous (73), perhaps
also accounting for some of the differences in degree of outcome. CPASS data, by demonstrating the presence of a critical
period poststroke in the clinical trial context, opens several avenues to expand the science of poststroke motor recovery in
adult humans poststroke.
It is also important to note that, while the effects of this study
may appear to be small and do not restore our patients to full
motor function, they are extremely important in our field. Few
UE rehabilitation trials have demonstrated an intervention effect
that is bigger than the CPASS primary outcome’s MCID (15–26).
This makes the effect size of our critical-period-dependent improvements in motor function especially significant for translating
6 of 10 | PNAS
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animal data into meaningful UE recovery in humans poststroke.
Comparable UE stroke rehabilitation trials have demonstrated
limited efficacy. For instance, the VECTORS phase II trial (16)
enrolled participants at 9.6 ± 4.5 d (compared with 15.4 ± 4.5 d in
CPASS); VECTORS reported no significant difference between
its two groups at 90 d. Thus, the VECTORS “low-dose group”
receiving 2 h/d of rehabilitation with restraint of the unaffected
hand in a mitt for 60% of the waking hours (to encourage use of
the affected hand) did no better than their control group receiving
traditional rehabilitation of the same intensity as their low-dose
group. Both the VECTORS and AVERT (17) trials showed
poorer outcomes with very early higher-intensity motor training.
The ICARE phase III RCT (15) compared two different treatment strategies, structured task-oriented UE training and an intensive high-repetition training, compared with a control group
receiving conventional occupational therapy. ICARE reported no
significant differences between groups at 12 mo poststroke. The
primary exception is the EXCITE phase III trial (74–76) showed
superior UE motor recovery at 12 mo in an “early” group receiving constraint-induced movement therapy (CIMT) 3 to 9 mo
poststroke compared with controls receiving conventional rehabilitation. The “early” group’s treatment timing (3 to 9 mo) in
EXCITE was slightly later than CPASS’ subacute intervention
time (2 to 3 mo) and overlaps some with our chronic group’s intervention timing (>6 mo poststroke), which showed no difference
compared with controls in CPASS. EXCITE trial’s early group
improvements may, however, be dose-related, not linked to a
critical period, because in a follow-up study the EXCITE investigators demonstrated that the same intensity of CIMT provided
to their controls after 12 mo led to the same motor improvement
in controls as in their experimental early group (3 to 9 mo poststroke) in the first study. It is likely that in the EXCITE study the
intensity of CIMT dose compared with traditional outpatient rehabilitation led to the superior motor recovery in the early group.
The EXCITE trial used a cross-over design, wherein the control
group was provided CIMT similarly intense as that of the early
group, but at a much later time point (at 12 mo) they showed
similar improvement in function. In contrast, CPASS improvements are time-sensitive; the CPASS chronic group (>6 mo) receiving the same intervention but outside the preferred window of
opportunity showed no significant improvement compared with
CPASS controls. It is likely the poststroke critical period stretches
beyond 3 mo but ends before 6 mo considering the EXCITE and
CPASS findings. Follow-up studies are needed for finer determination of the boundaries of the poststroke critical period. The
CPASS results, by demonstrating presence of critical period
poststroke in a clinical context, open several avenues for the exploration of the science of poststroke motor recovery.
Clinical Evidence for a Poststroke Critical Period. The heightened
gains in UE motor recovery found here appear to result from a
synergistic coupling between a specific window of time poststroke during the lesioned brain’s recovery and the type of motor
rehabilitation focused on training functional UE movements that
were of the highest priority to each individual person.
Typical inpatient rehabilitation sessions in the United States
last ∼39 min/d for ∼12 d poststroke (77); on average, persons
with stroke move their impaired UE 3.7 ± 3.1 h/d (78) at this
poststroke time point. Outpatient rehabilitation sessions in the
United States last ∼36 min/d with patients engaging in an average of 12 purposeful movements in an otherwise unstructured
treatment session, continuing for a few weeks (79). CPASS
added to this an innovative study-specific 20-h intervention that
emphasized participant autonomy and intrinsic motivation coupled with task shaping and massed practice. This approach
demonstrates that patients can tolerate much more intensive
motor training than is traditionally provided. In addition, the
finding of greatest benefit from additional therapy at the
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Conclusions and Future Directions. CPASS provides strong evidence for a sensitive or critical period in human brain recovery
and confirms the relevance of rodent models to the study of
stroke recovery in humans. Our results also have important implications for the redesign of optimal stroke rehabilitation programs, which we believe can be done within the constraints of
existing clinical care systems. There remains a series of questions
that are crucial to be addressed in subsequent studies. First, a
more precise definition of the timing and duration of the sensitive
or critical period is needed. Evidence in both rodents and humans
suggests that intensive training too soon after injury can reduce
recovery (16, 17) and possibly even increase the size of the lesion
(41, 42, 86), and training too late after injury provides no additional benefit (1, 87). Second, more information is needed about
the interaction between the timing of treatment and treatment
intensity. The goal of the CPASS study was to elicit a signal for the
existence of a sensitive period and not to determine the optimal
dose of motor training within these treatment periods. It is quite
possible that the most effective treatment dose varies within the
sensitive period and that higher or lower doses of intensive motor
treatment may further optimize UE outcomes. Now that the optimal time period for intensive motor treatment is known, a focused study of treatment dose can be conducted.
Moreover, it is possible that time and treatment dose may
interact in more complex ways within the two early time periods.
In the present results we found a signal for plasticity in the acute
group that was not as robust as in the subacute period. A lower
training dose might have enhanced outcomes in the acute group,
consistent with the literature on deleterious effects of intensive
therapy provided “too early” in animal models (16, 41, 42, 86) and
human stroke (16, 17). In contrast, a higher dose of therapy might
be useful in the chronic phase to determine if residual plasticity
can be harnessed when recovery seems to have plateaued (14). A

subsequent dose-defining trial can thus accelerate our understanding of critical period plasticity and also provide definitive
neurorehabilitation guidelines in the restoration of UE motor
function across the recovery timeline of stroke. Future stroke rehabilitation trials should also include neurophysiologic and imaging
measures in acute, subacute, and chronic periods to elucidate the
mechanisms at the cellular and molecular level involved in critical
period like neuroplasticity in adult humans poststroke. This information is essential to the development of future treatment modalities, which might include neurostimulation, growth factors, or
cellular replacement therapies that could amplify the effects of intensive motor training. In the future, a further understanding of the
mechanisms underlying these timing effects can allow us to extend
and enhance the treatment timeline, with the ultimate aim of producing full motor recovery in human patients.
Materials and Methods
The trial was approved by the Institutional Review Board at MedStar National
Rehabilitation Hospital/MedStar Health Research Institute (protocol no. 2014065). All study participants provided informed consent prior to engaging in
study procedures. Fig. 2 shows the study design.
Participants.
Screening and recruitment. Persons with stroke were primarily recruited from
the inpatient stroke service at the MedStar National Rehabilitation Hospital,
the Washington, DC site for the National Institute of Neurological Disorders
and Stroke StrokeNet, and DC area hospitals (MedStar Washington Hospital,
MedStar Georgetown University Hospital, and peripheral MedStar hospitals).
Participants were screened via daily inpatient hospital admission logs and
approached for recruitment to the study within the first few days of admission. Participants provided informed consent prior to randomization. To
preclude severe cognitive or sensory impairments participants were excluded
for hemispatial neglect as determined by an asymmetry of more than three
errors on the Mesulam Symbol Cancellation Test (88) and a score of ≥8 on the
Short-Blessed Memory Orientation and Concentration scale (89). Full trial
inclusion and exclusion criteria are listed in Table 1. Fig. 2 shows the participant flow through the study.
Randomization. Participants were adaptively randomized (90) into one of four
study groups (acute, subacute, chronic, or control) by the study statisticians
after informed consent and baseline assessment data were entered into a
database. Study groups were balanced with respect to participant age, number of days from stroke onset to baseline evaluation, stroke type (ischemic
versus hemorrhagic), baseline ARAT score, concordance (whether the dominant or nondominant UE is affected), and overall stroke severity measured
using the NIHSS (91) at baseline. The adaptive randomization we developed
was based on methods described by Meinert (92), Signorini et al. (93), and
Atkinson (94). This scheme was created to prevent imbalances while avoiding
the problems of small numbers within blocks that stratification can produce.
Study Measures. The primary outcome measure was the ARAT (61, 95). The
ARAT is a standardized assessment that evaluates functional limitations of
the UE. It uses a 4-point ordinal scale of 19 items, where 0 indicates no
movement and 3 indicates normal movement. Item scores are summed to
create four subscale scores: grasp (18 point maximum), grip (12 point maximum), pinch (18 point maximum), and gross motor (9 point maximum). The
total scale has a maximum score of 57, indicating normal UE performance
(96). The ARAT has been shown to be reliable, valid, and responsive to
change across a variety of time points poststroke (69, 96–99).
The ARAT and other secondary study measures were administered at
baseline, pretreatment, posttreatment, 6-mo, and 1-y time points. The
baseline, 6-mo, and 12-mo evaluations were standard for all treatment
groups. However, the pre- and posttreatment assessments were linked to the
start and completion of study treatments, which varied across the groups (see
Fig. 2 for participant flow through the trial and SI Appendix, Fig. S1 for all
assessments for each group). All study measures were administered by evaluators blinded to the treatment condition. SI Appendix, Table S1 outlines the
various study measures at each evaluation time point from the study.
Intervention. All participants received standard of care (both inpatient and
outpatient) interdisciplinary rehabilitation treatments as prescribed by their
physician and clinical therapy teams. The CPASS intervention was modeled as
closely as clinically feasible in the US system and ethically appropriate (100) to
the Biernaskie et al. (1) rodent study. In addition to standard rehabilitation
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subacute phase (2 to 3 mo after stroke) warrants consideration of
extending outpatient rehabilitation to this time period.
Given that we have shown that human recovery appears to
have a critical period like that observed in the rodent model, we
can also speculate that similar physiological processes may underpin the enhanced recovery observed in our subacute and
acute participant groups. The enhancement effect of the taskspecific training in rodents is constrained around optimal times
poststroke (1, 10) that physiologically are associated with strong
increases in synaptic activity in the perinfarct regions, greater dendritic branching and complexity (5), and stability of the newly
formed dendritic spines in line with behavioral recovery of forelimb
function over time (80). These processes are similar to the effects of
purposeful activity working synergistically to achieve optimal plasticity in other domains, for example in sensorimotor integration
during locomotion in rodents (81), auditory map plasticity in adult
barn owls (82), and in language acquisition (83, 84). In adult humans with amblyopia, 40 to 80 h of video-game training leads to
substantial improvement of visual function in amblyopia (85)
compared with the conventional eye patching alone.
CPASS findings suggest optimal periods for intensive motor
training when UE motor rehabilitation interventions are most
effective. Our results point to the subacute period. However, it is
possible that there is a point in the acute period that is equally
effective. Unfortunately, our design did not allow such resolution. Our findings diverge somewhat from the rodent model
where animals treated earlier (but not too early) tend to have the
best recovery. This discordance might be attributed to the differences between rodent and human brains as well as to the
social and emotional forces at play in humans who must accommodate the sudden and unanticipated changes associated
with stroke. It should also be noted that CPASS was a phase II
trial; a larger multicenter trial is needed to extend the findings
and confirm the superiority of the subacute treatment window.

treatment that all participants received from their clinicians, we provided an
additional 20 h of intensive UE motor training based on a standardized, yet
highly individualized, shaping protocol adapted from VECTORS, our previous UE stroke recovery trial and recent stroke rehabilitation trials (15, 16, 75,
87, 101, 102). Unlike the VECTORS or EXCITE trials, no constraint was applied
to the less-affected hand or arm. Since the goal of CPASS was to identify the
timing of a potential critical period of increased responsiveness to activitybased therapy and elicit an enhanced and persistent motor response during
that therapy, we did not explore optimal dosing for the training provided in
the present trial (100). Based on our prior work, an additional 10 h of UE
therapy was sufficient to alter motor outcomes (16). As a result, to ensure a
signal (if one was present) we chose to deliver 20 h of additional UE therapy
in a brief period of time to each participant to enhance poststroke motor
recovery. The treatment was based on four fundamental principles of
learning that guide rodent motor training trials as applied to humans: 1)
massed practice (30), 2) intrinsic motivation (103–105), 3) detailed taskspecific analysis and grading (106–108), and 4) positive reinforcement
(109–112). Typically, therapy sessions ranged from 30 min (inpatient/acute
group) to 3 h per session (out-patient/subacute and chronic groups). This
training focused on the use of the more-affected UE in ADL and leisure tasks
agreed upon by the patient and study therapist. The treatment was delivered in the inpatient rehabilitation setting (for those randomized to the
early group) or outpatient clinic settings (for subacute and chronic groups)
whenever possible. Adherence to CPASS therapy protocol was defined as at
least 15 h of therapy within 42 d in the allocated group’s timeline.
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Power Analysis, Sample Size Estimation, and Final Sample. Before study initiation a power analysis was conducted to estimate the sample size needed to
test the study hypotheses. The estimated study sample of 64 subjects (16 per
study arm) was based on demonstrating a moderate effect size (0.425 as
observed in preliminary data) in the primary endpoint, the ARAT at 1 y in an
ANOVA model, with 80% power at a significance level of 5%. Persons with
stroke with moderate UE motor impairment who demonstrated motor arm
score ≥1 on the NIHSS were recruited. Individuals with terminal illness were
excluded. An interim analysis with blinded data were conducted by the
study’s principal investigator (A.W.D.) and statistician (M.T.T.). This analysis
indicated that the treatment groups were imbalanced and an additional
eight participants were recruited, randomized, and treated.
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